Morphine

# Research Output: Morphine
**PSX ID:** PSX-0266 | **Generated:** 2026-04-27 | **Research Agent:** Pharmacological Research Agent

---

## Chemical Identity

**Verified via PubChem CID 5288826 [Ref 1]:**

| Property | Value |
|---|---|
| PubChem CID | 5288826 |
| Molecular Formula | C₁₇H₁₉NO₃ |
| Molecular Weight | 285.34 g/mol |
| IUPAC Name | (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol |
| InChIKey | BQJCRHHNABKAKU-KBQPJGBKSA-N |
| CAS Number | 57-27-2 (free base) |
| Melting Point | 255°C (free base) [Ref 28] |
| Water Solubility | Sparingly soluble as free base; sulfate and hydrochloride salts are ~300× more water-soluble [Ref 28] |

**SMILES string:** Not returned by the PubChem API tool (confirmed gap — the molecular formula, weight, and InChIKey were confirmed, but SMILES was not retrieved in this session). The SMILES is publicly available via PubChem CID 5288826 and should be populated from the PubChem compound page directly.

**Discrepancies with brief:**
- Brief lists SMILES, Molecular formula, Molecular weight, InChIKey, and PubChem CID as empty — all confirmed here except SMILES.
- Brief IUPAC name matches exactly the PubChem-verified value.
- CAS number 57-27-2 not listed in brief — confirmed via chemical database [Ref 28].

**Stereochemistry and active isomer:** Morphine is a pentacyclic compound with five stereocenters: (4R,4aR,7S,7aR,12bS). Natural (−)-morphine is the pharmacologically active enantiomer and is the sole commercial form. (+)-Morphine (unnatural enantiomer) is inactive at opioid receptors. All pharmacological data in this report refers to (−)-morphine (Brook et al. 2017 [Ref 4]; Devereaux et al. 2018 [Ref 3]).

**Physical properties:** Morphine free base is a white crystalline powder, melting at 255°C. Its sparingly hydrophilic free base form limits formulation flexibility; pharmaceutical preparations therefore use the sulfate (MS-Contin, Oramorph, Sevredol), hydrochloride, or tartrate salts, which dissolve readily in aqueous solution [Ref 28].

---

## Pharmacology

### Receptor Binding Affinity

Morphine is a full agonist at the mu-opioid receptor (MOR, OPRM1), the primary mediator of its analgesic, euphoric, and respiratory depressant effects. Verified binding data:

| Receptor | Ki (human) | Source |
|---|---|---|
| Mu-opioid receptor (MOR) | 1.0 nM (pKi 9.0) | IUPHAR/BPS Guide to Pharmacology [Ref 23] |
| Kappa-opioid receptor (KOR) | ~100–600 nM (estimated from comparative literature) | Class inference; see Gaps |
| Delta-opioid receptor (DOR) | ~100–500 nM (estimated from comparative literature) | Class inference; see Gaps |

Morphine is significantly less potent at KOR and DOR than at MOR. Its pharmacological classification as "Kappa-opioid receptor agonist" in the seed data is technically valid but potentially misleading, as clinically relevant KOR activity is minimal at therapeutic doses (see Gaps & Flags).

In a human MOR β-arrestin2 functional assay, morphine EC₅₀ = 290 nM — substantially less potent than fentanyl (EC₅₀ = 14.9 nM) at β-arrestin2 recruitment, placing morphine in the moderately biased category (Vandeputte et al. 2022 [Ref 9]).

The MOR binding pose of morphine involves a salt bridge between the protonated tertiary amine and the conserved Asp147(3.32) residue in the orthosteric binding site (Eshleman et al. 2020 [Ref 29]; Huang et al. 2015 [Ref 12]).

### Receptor Structure

The inactive-state crystal structure of the µ-opioid receptor was determined in 2012 by Manglik et al. [Ref 13], providing the first structural basis for morphine-class ligand binding. The active-state structure (bound to morphinan agonist BU72 with G protein mimetic antibody fragment) was resolved at 2.1 Å by Huang, Manglik et al. (2015) [Ref 12], revealing how agonist binding is conformationally coupled to a conserved intracellular triad via an extensive polar network.

### Mechanism of Action

Morphine activates MOR, a Gi/o-protein-coupled receptor, producing three key downstream effects (Corder et al. 2018 [Ref 14]; Pasternak et al. 2020 [Ref 43]):

1. **Adenylyl cyclase inhibition:** Gαi subunit inhibits adenylyl cyclase → ↓cAMP → reduced PKA activity → reduced neuronal excitability
2. **K⁺ channel opening:** Gβγ dimers open inwardly rectifying GIRK channels → membrane hyperpolarization
3. **Ca²⁺ channel inhibition:** Gβγ inhibits voltage-gated N-type and P/Q-type Ca²⁺ channels → reduced neurotransmitter (including substance P, glutamate) release

The net effect is reduced transmission of nociceptive signals in the spinal cord, brainstem, and higher cortical areas. MOR is expressed at pre- and post-synaptic sites throughout the pain processing pathway, and its activation in the nucleus accumbens and ventral tegmental area mediates euphoric/reward effects via dopamine release.

**P-glycoprotein substrate:** Morphine is an ABCB1 (P-gp) substrate, which limits its CNS penetration relative to more lipophilic opioids such as fentanyl. Quinidine-mediated P-gp inhibition significantly increases morphine bioavailability and brain penetration in humans (Kharasch et al. 2003 [Ref 10]).

### Pharmacokinetics (Human)

**Oral route (immediate release):**
- Bioavailability: ~20–40% (first-pass glucuronidation in liver and gut wall; Säwe 1986 [Ref 6]; Glare & Walsh 1991 [Ref 21])
- Oral-to-parenteral potency ratio: approximately 1:3 (Glare & Walsh 1991 [Ref 21])
- Time to peak plasma: 30–90 minutes (Glare & Walsh 1991 [Ref 21])

**Intravenous route:**
- Onset: seconds to minutes
- Bioavailability: 100% (by definition)

**Intramuscular / Subcutaneous:**
- Time to peak plasma: 15–20 minutes (Glare & Walsh 1991 [Ref 21])

**Distribution:**
- Protein binding: 20–35% (primarily to albumin and α₁-acid glycoprotein; Säwe 1986 [Ref 6])
- Volume of distribution: 1–6 L/kg (large interindividual variability; Säwe 1986 [Ref 6])
- Crosses the blood–brain barrier, placenta, and enters breast milk

**Elimination:**
- Plasma clearance: ~19 mL/min/kg (range 5–34; Säwe 1986 [Ref 6])
- Elimination half-life: approximately 2–4 hours (published range 0.7–7.8 h; large variability; Säwe 1986 [Ref 6])
- Primary elimination: renal excretion of glucuronide metabolites

**Metabolism (UGT2B7 glucuronidation):**
Morphine is primarily metabolized in the liver by UDP-glucuronosyltransferase 2B7 (UGT2B7), yielding two major glucuronide conjugates (Yang et al. 2017 [Ref 8]; Coates et al. 2024 [Ref 7]):

- **Morphine-3-glucuronide (M3G):** ~75–80% of glucuronide output. Inactive at MOR; paradoxically may antagonize morphine's analgesic effects and contribute to neuroexcitatory side effects (hyperalgesia, myoclonus) at high concentrations. M3G:morphine plasma ratio ≈ 10:1 (IV) and 20:1 (oral) (Säwe 1986 [Ref 6]; Glare & Walsh 1991 [Ref 21]).
- **Morphine-6-glucuronide (M6G):** ~15–20% of glucuronide output. Active MOR full agonist, significantly more potent than morphine per unit. Accumulates in renal insufficiency (Glare & Walsh 1991 [Ref 21]; Lötsch et al. 2002 [Ref 22]).
- **Normorphine:** Minor active metabolite; formed via N-demethylation; more prominent after oral administration; potentially neurotoxic (Glare & Walsh 1991 [Ref 21]).

UGT2B7 genetic polymorphisms (e.g., UGT2B7*2) alter the M3G:M6G ratio produced, contributing to interindividual variability in analgesic response (Yang et al. 2017 [Ref 8]). OPRM1 A118G SNP may reduce M6G potency at MOR (Lötsch et al. 2002 [Ref 22]).

**Renal and hepatic effects on PK:**
- Renal insufficiency: M6G accumulates → enhanced and prolonged opioid effects and toxicity risk (Glare & Walsh 1991 [Ref 21])
- Hepatic cirrhosis: Increased oral bioavailability due to reduced first-pass metabolism; moderate reduction in intravenous clearance (Säwe 1986 [Ref 6])

---

## History

### Discovery and Isolation

Opium — the dried latex of *Papaver somniferum* seed capsules — has been used by humans for at least 8,000 years, with evidence of cultivation and use dating to the sixth millennium BCE in Mesopotamia (Brook et al. 2017 [Ref 4]; Devereaux et al. 2018 [Ref 3]).

The isolation of morphine as opium's primary psychoactive constituent was accomplished by **Friedrich Wilhelm Adam Sertürner** in 1804, making it the first alkaloid to be isolated from a plant. Sertürner named the compound after Morpheus, the Greek god of dreams. His isolation represented the founding moment of modern alkaloid chemistry (Marton et al. 2025 [Ref 2]; Devereaux et al. 2018 [Ref 3]).

### Chemical Elucidation and Synthesis

Understanding morphine's structure was a 150-year project:
- Empirical formula established through successive studies in the 19th century
- **Sir Robert Robinson** derived morphine's correct structural formula in the early 20th century, work for which he received the **Nobel Prize in Chemistry in 1947** (Brook et al. 2017 [Ref 4])
- First **total synthesis** of morphine was achieved by Marshall Gates and Gilg Tschudi in 1952 at the University of Rochester — a landmark in synthetic organic chemistry
- Despite this achievement, plant-based extraction from *Papaver somniferum* (primarily Tasmania, India, Turkey) remains economically dominant to this day (Brook et al. 2017 [Ref 4])

**János Kabay** (Hungarian pharmacist) advanced industrial production in the 1920s–1930s by developing direct extraction from dry poppy straw — avoiding the labor-intensive opium harvesting process — founding the Alkaloida Chemical Company in 1927 (Marton et al. 2025 [Ref 2]).

### Clinical and Regulatory History

- **1827:** Merck began commercial production of morphine
- **Mid-19th century:** Hypodermic needle invented (1853), enabling IV morphine — dramatically escalating medical and non-medical use
- **US Civil War (1861–1865):** Morphine used extensively for battlefield pain → 400,000+ estimated soldiers became dependent ("Soldiers' Disease")
- **1898:** Bayer synthesized heroin (diacetylmorphine) from morphine, marketed as a "non-addictive" morphine substitute — subsequently recognized as more addictive
- **1914 (US):** Harrison Narcotic Tax Act — first federal regulation of morphine and other opiates
- **1961:** UN Single Convention on Narcotic Drugs — morphine listed on Schedule I (most strictly controlled), yet explicitly recognized as indispensable for pain relief (Devereaux et al. 2018 [Ref 3])
- **1986:** WHO analgesic ladder introduced — morphine established as the Step III strong opioid reference standard
- **1990s–present:** Opioid crisis driven initially by prescription opioids (OxyContin); fentanyl now dominant; morphine prescription has declined relative to synthetic opioids

---

## Subjective Effects

### Human Controlled Studies

Jasinski and Preston (1986) [Ref 18] administered single intramuscular doses of morphine to 10 adult male non-dependent substance abusers in a double-blind study. Morphine significantly increased scores on the **Morphine-Benzedrine Group (MBG) scale** (measuring euphoria) and on explicit "drug liking" scales, dose-dependently. Combination with d-amphetamine produced greater euphoria than either drug alone, while physiological side effects were partially antagonized — findings relevant to polydrug use abuse potential.

### Effect Profile (from literature and seed data — consistent with published opioid pharmacology)

**Perceptual effects:**
- Internal hallucinations and dreaming enhancement: Documented at higher doses in case reports and user reports; attributed to CNS depression and reduced sensory gating at MOR-expressing limbic areas. Published controlled studies have not systematically characterized these effects for morphine specifically.
- Double vision: Consistent with sedation-associated effects; noted in overdose literature.

**Somatic/body effects:**
- **Pain suppression:** Primary clinical indication; well-documented across all routes of administration
- **Respiratory depression:** Central brainstem MOR agonism (pre-Bötzinger complex rhythm generator); dose-dependent; primary cause of overdose death (Hill et al. 2020 [Ref 16]; Webster & Rauck 2021 [Ref 35])
- **Pupil constriction (miosis):** Hallmark opioid effect via Edinger-Westphal nucleus MOR agonism
- **Sedation:** Dose-dependent; pronounced at higher doses
- **Nausea/vomiting:** Via area postrema MOR agonism (chemoreceptor trigger zone); typically attenuates with repeated use
- **Constipation:** Via MOR agonism in enteric nervous system → reduced GI motility; does not significantly develop tolerance (persistent with continued use)
- **Muscle relaxation:** Via CNS depression
- **Increased urination:** Urinary retention is a documented adverse effect (urethral sphincter tone increase)
- **Tactile euphoria / spontaneous body sensations:** Reported in human studies and user reports
- **Sexual arousal suppression:** Via MOR agonism reducing gonadotropin release

**Cognitive/affective effects:**
- **Cognitive euphoria, anxiety suppression:** Well-documented in controlled studies (Jasinski & Preston 1986 [Ref 18]); mediated by MOR in limbic system, nucleus accumbens, and amygdala
- **Thought deceleration:** Consistent with global CNS depression
- **Compulsive redosing urge:** Related to acute reward learning and MOR-mediated dopaminergic sensitization

### Duration

From the seed data and consistent with published pharmacokinetics (Glare & Walsh 1991 [Ref 21]; Sverrisdóttir et al. 2015 [Ref 5]):
- **Oral (immediate release):** Onset 10–30 min; peak 2–3 h; total duration 4–6 h
- **IV:** Onset seconds; peak 5–10 min; total duration 3–5 h
- Extended-release formulations (MS-Contin) provide 8–24 h coverage

---

## Safety & Toxicity

### Acute Toxicity

**Primary mechanism of toxicity:** Dose-dependent respiratory depression through MOR agonism in the brainstem (pre-Bötzinger complex), leading to hypercapnia, hypoxia, coma, and death (Hill et al. 2020 [Ref 16]; Webster & Rauck 2021 [Ref 35]).

**Triad of opioid toxidrome:** Miosis (pinpoint pupils), respiratory depression, decreased consciousness — though in polysubstance overdose the triad may be incomplete.

**LD50 / Therapeutic index (human):** No directly published human LD50 is available in the literature searched. Human fatal doses are highly variable, depending critically on opioid tolerance. In opioid-naïve individuals, acute respiratory depression can occur at doses as low as 30 mg IV. In heroin overdose literature, tolerance loss after periods of abstinence is a primary risk factor (Warner-Smith et al. 2001 [Ref 36]).

**Animal toxicity:** Morphine ED₅₀ for antinociception in rats (hot plate test, s.c.) ≈ 3.94 mg/kg (Vandeputte et al. 2022 [Ref 9]).

**⚠️ FLAG:** Seed data states "Acute: high; Chronic: high — Inferred from pharmacological class — not sourced from literature." This is accurate in direction but cannot be replaced with published numerical values from this search. The statement is appropriate for the article but should be clearly labeled as inference-based.

**Naloxone reversal:** All opioid effects, including respiratory depression, are reversed by competitive MOR antagonist naloxone (Lewanowitsch et al. 2006 [Ref 34]). Multiple naloxone doses may be required given morphine's longer half-life vs. naloxone (60–90 min).

### Morphine-6-Glucuronide (M6G) Toxicity in Renal Failure

M6G, the active metabolite, accumulates in patients with renal insufficiency. This can produce prolonged and enhanced opioid effects — including life-threatening respiratory depression — even after morphine itself has been cleared. The OPRM1 A118G SNP may modify M6G potency and thus confer differential risk (Lötsch et al. 2002 [Ref 22]).

### Opioid-Induced Hyperalgesia (OIH)

Paradoxical pain sensitization occurs with chronic morphine use. Mechanisms involve spinal astrocyte JNK/NMDA/PKC pathway activation (Sanna et al. 2015 [Ref 44]), descending facilitation, and spinal dynorphin upregulation. OIH manifests as diffuse pain unrelated to original pain site and worsens with dose escalation (Angst & Clark 2006 [Ref 11]).

### Organ Toxicity

**Respiratory:** Primary acute toxicity target. Dose-dependent depression of rate and tidal volume.
**Endocrine:** Chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis → hypogonadism, sexual dysfunction, suppressed libido, menstrual irregularities.
**GI:** Opioid-induced bowel dysfunction — constipation, nausea, vomiting, gastroparesis. Tolerance does not develop to constipation.
**CNS:** Sedation, cognitive impairment, OIH with chronic use.
**Cardiovascular:** Histamine release (morphine-specific; not all opioids) → vasodilation, hypotension, flushing.

### Specific Safety Flag: Histamine Release

Morphine (unlike fentanyl) promotes histamine release from mast cells, contributing to urticaria, pruritus, and hypotension. This is not an IgE-mediated allergy but a pharmacological effect.

---

## Harm Reduction

### Key Risk Factors for Overdose

1. **Tolerance loss:** Risk is highest after any period of abstinence (incarceration, treatment, hospital admission). Return to pre-abstinence doses can be fatal (Warner-Smith et al. 2001 [Ref 36]; Kesten et al. 2022 [Ref 33]).
2. **Polysubstance use:** Co-ingestion of CNS depressants (alcohol, benzodiazepines, GHB/GBL, ketamine) synergistically potentiates respiratory depression. Most opioid overdose deaths involve polydrug combinations (Warner-Smith et al. 2001 [Ref 36]).
3. **Injection route:** IV administration bypasses first-pass metabolism and delivers full dose to CNS within seconds; substantially higher overdose risk than oral.
4. **Renal impairment:** M6G accumulation → enhanced toxicity at standard doses.
5. **Hepatic impairment:** Increased oral bioavailability → higher plasma levels.

### Contraindications (from clinical literature and prescribing practice)

- Known hypersensitivity to morphine or morphinan opioids
- Significant respiratory depression or acute asthma (unmonitored)
- Paralytic ileus
- Raised intracranial pressure (relative contraindication: morphine may increase ICP via hypercapnia from respiratory depression)
- Concurrent monoamine oxidase inhibitor (MAOI) use: risk of serotonergic effects and severe respiratory depression
- Renal failure: not absolutely contraindicated but M6G accumulation requires dose reduction and monitoring

### Emergency Response

- **Naloxone (Narcan):** 0.4–2.0 mg IV/IM/intranasal; repeat every 2–3 minutes as needed. Given morphine's half-life (~2–4 h), multiple doses or an infusion may be needed as naloxone wears off faster (~60–90 min). Place patient in recovery position if unconscious. Do not leave opioid-intoxicated persons unattended.
- **CDC Prescribing Guideline (2016):** Established morphine milligram equivalents (MME) as reference standard for dose comparison; ≥90 MME/day associated with substantially increased overdose risk (Dowell et al. 2016 [Ref 41]).

### Testing and Identification

Morphine is detected on standard opioid immunoassay panels (urine drug screens). Confirmatory GC-MS or LC-MS/MS distinguishes morphine from codeine (morphine is a minor metabolite of codeine) and other opioids.

---

## Tolerance & Dependence

### Tolerance Mechanism

Acute MOR agonism inhibits adenylyl cyclase. With chronic morphine exposure, cellular compensatory mechanisms develop — most critically, **adenylyl cyclase superactivation** (upregulation of adenylyl cyclase V and VIII) mediated by Gβγ dimers (Avidor-Reiss et al. 1996 [Ref 15]). This superactivated state leads to a rebound increase in cAMP upon opioid withdrawal, contributing to the withdrawal syndrome.

Notably, morphine induces relatively **poor MOR internalization** compared to other opioids (e.g., DAMGO, remifentanil) due to lower β-arrestin recruitment (Nowoczyn et al. 2013 [Ref 40]). This poor internalization may paradoxically contribute to greater tolerance development ("desensitization without resensitization").

### Cross-Tolerance

Full cross-tolerance exists across all MOR agonists: morphine, heroin (via M6G/morphine metabolites), oxycodone, hydromorphone, fentanyl, methadone, and buprenorphine (partial). This is exploited clinically in opioid rotation (Vadalouca et al. 2008 [via citation context]).

### Physical Dependence

Physical dependence develops with regular use as short as several days to weeks. Withdrawal syndrome upon cessation or naloxone precipitation includes:
- **Autonomic:** diaphoresis, piloerection, lacrimation, rhinorrhea, yawning, tachycardia, hypertension
- **GI:** nausea, vomiting, diarrhea, abdominal cramping
- **Musculoskeletal:** muscle aches, restless legs, arthralgia
- **CNS:** anxiety, irritability, insomnia, dysphoria

Severity peaks 24–72 hours after last short-acting opioid dose; largely resolves within 5–10 days. Assessed clinically with the Clinical Opiate Withdrawal Scale (COWS). Long-term protracted abstinence syndrome (dysphoria, sleep disturbance, opioid craving) may persist weeks to months (Ozdemir et al. 2024 [Ref 32]).

### Dependence Liability

Morphine has high physical and psychological dependence liability. In controlled human studies, it increases Morphine-Benzedrine Group (MBG) scores and drug-liking, with these effects predictive of abuse potential (Jasinski & Preston 1986 [Ref 18]; Walsh et al. 2008 [context]). NCT00314340 (Phase IV, completed) compared addiction liability of sustained-release morphine vs. hydrocodone.

---

## Interactions

### Cannabis (⚠️ Caution — mechanistically verified)

THC and CBD inhibit UGT2B7-mediated morphine glucuronidation in vitro, with CBD Ki,u = 0.16 μM and THC Ki,u = 0.37 μM. Mechanistic static modeling predicted clinically significant in vivo drug-drug interactions between morphine and inhaled cannabis (THC) and oral cannabis products (THC, CBD) — elevating morphine and M6G plasma levels (Coates et al. 2024 [Ref 7]).

**Assessment:** "Caution" designation in brief is confirmed by published evidence. The DDI is pharmacokinetic (UGT2B7 inhibition) → increased morphine exposure.

### Alcohol (⚠️ High risk)

Ethanol is a CNS depressant that acts synergistically with morphine to potentiate respiratory depression. Co-ingestion is a major risk factor in opioid overdose deaths (Warner-Smith et al. 2001 [Ref 36]). The mechanism is additive CNS depression with no pharmacokinetic interaction with morphine specifically (unlike extended-release formulations of other opioids).

**Assessment:** "Lethal" designation is appropriate for recreational polydrug contexts. Published postmortem toxicology studies consistently identify alcohol as a co-intoxicant in opioid deaths.

### GHB / GBL (⚠️ High risk — lethal in overdose context)

GHB and GBL act as CNS depressants via GABA-B agonism and GHB receptor activation. Combined with opioids, they produce synergistic respiratory depression. No morphine-specific published interaction studies were located in this search; class-based inference from CNS depressant pharmacology strongly supports the "lethal" designation for high-dose recreational co-use.

**Assessment:** "Lethal" designation appropriate. Published evidence is class-level rather than morphine-specific.

### Ketamine (⚠️ Nuanced — see flag)

Ketamine is an NMDA receptor antagonist with dissociative and analgesic properties. At sub-anesthetic doses, it is used clinically as an opioid-sparing adjuvant alongside morphine (Singh et al. 2018 [Ref from PK context]). At higher recreational doses, combined CNS depression from both agents increases sedation and respiratory depression risk.

**Assessment:** The "lethal" designation in the brief likely applies to high-dose recreational co-use. Clinical combination (low-dose ketamine + therapeutic morphine) is not inherently lethal and is common practice. **Flag for editorial review:** the "lethal" interaction severity may need contextual nuance distinguishing clinical adjuvant use from recreational high-dose polydrug use.

### Tramadol (⚠️ Nuanced — see flag)

Tramadol is an atypical opioid with weak MOR agonism plus serotonin/norepinephrine reuptake inhibition. Co-administration with morphine increases respiratory depression risk via additive MOR effects. Tramadol itself has serotonergic activity that could theoretically contribute to serotonergic overstimulation, though pure morphine has minimal serotonergic activity (Schenk & Wirz 2015 [Ref 25]).

**Assessment:** "Lethal" designation should be flagged for editorial review. Tramadol+opioid combinations are used clinically (e.g., postoperative pain); however, recreational high-dose co-use presents elevated risk via additive respiratory depression. The interaction is real and potentially dangerous but "lethal" may overstate risk at typical doses.

### Nitrous Oxide (Unknown)

No published morphine-specific interaction data found. Nitrous oxide acts as a weak MOR agonist with NMDA antagonist properties; it has been used as an analgesic adjuvant with opioids. At clinical concentrations, the combination is not typically life-threatening. "Unknown" designation in brief is appropriate.

### PCP (Unknown)

No published morphine-PCP specific interaction data found. PCP is a dissociative NMDA antagonist + sigma receptor ligand. Combined CNS depression is plausible. "Unknown" designation in brief is appropriate.

---

## Legal Status

| Jurisdiction | Schedule / Classification | Legislation |
|---|---|---|
| United States | Schedule II (DEA) | Controlled Substances Act 1970 |
| United Kingdom | Class A / Schedule 2 | Misuse of Drugs Act 1971 |
| Australia | Schedule 8 (Controlled Drug) | State/Territory Poisons Acts |
| Canada | Schedule I | Controlled Drugs and Substances Act 1996 |
| International | Schedule I | UN Single Convention on Narcotic Drugs 1961 |

All sources: [Ref 17]

**Notes:**
- Schedule II (US) and Schedule 2 (UK) denote high abuse potential but recognized medical use — distinct from Schedule I (US) which has no accepted medical use.
- The UN Single Convention Schedule I is distinct from US CSA Schedule I — the UN designation allows medical use and specifically lists morphine as indispensable.
- WHO Essential Medicines List has included morphine for decades as an essential analgesic.
- No recent changes to scheduling were identified in the searches (as of April 2026).

---

## Clinical Trials

**Identified Completed/Active Trials:**

1. **NCT00314340** — "A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine" — Phase IV, Completed — University of California, Davis. Directly compares morphine SR abuse liability vs. hydrocodone.

2. **MABEL Trial (PMID 41033333)** — "Morphine for chronic breathlessness (MABEL) in the UK" — Multi-site parallel-group, double-blind, randomised, placebo-controlled trial — Lancet Respiratory Medicine (2025). Tests oral morphine titration for breathlessness in chronic non-malignant conditions [Ref 38].

3. **Fentanyl vs. Morphine for dyspnea RCT (PMID 41115797)** — "Efficacy of fentanyl buccal tablet and morphine for exertional dyspnoea in patients with cancer" — Double-blind, placebo-controlled RCT — Thorax (2026) [Ref 45].

**Morphine as active comparator:** Morphine sulfate IV (initial load 4 mg, demand dose 1 mg PCA) was the reference arm in multiple oliceridine Phase III trials (Liu et al. 2025 [Ref from citation context]) comparing G-protein-biased MOR agonists to standard care.

**Note on clinical trial search:** The ClinicalTrials.gov API search for "morphine sulfate" and related terms returned primarily other opioid studies using morphine as an active comparator. NCT00314340 is the most directly morphine-specific trial identified.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Proceeding with standard research only.

---

## Gaps & Flags

### 1. 🔴 SAFETY-CRITICAL: Toxicity Data Labeled as Inferred
The seed data states: *"Inferred from pharmacological class — not sourced from literature. Review recommended."* This was not resolved in this search — no published human LD50 for morphine was located. Animal data confirms high acute toxicity (respiratory depression at supra-analgesic doses). The "high" acute/chronic toxicity designation is directionally accurate but is not supported by a directly published numerical value from this session.

### 2. 🔴 INTERACTION FLAG: Ketamine — "Lethal" vs. Clinical Adjuvant Use
Morphine + ketamine (sub-anesthetic) is a routine clinical analgesic combination. The "lethal" severity designation in the seed data likely applies to recreational high-dose polydrug use. The generation agent should consider adding contextual nuance or a dose-threshold qualifier. Flag for editorial review.

### 3. 🔴 INTERACTION FLAG: Tramadol — "Lethal" Overstated for All Contexts
Tramadol + morphine is used in clinical practice. High-dose recreational combination has elevated respiratory depression risk. "Lethal" designation should be reviewed for appropriate context-dependency. Flag for editorial review.

### 4. 🟡 PHARMACOLOGICAL CLASS: KOR Agonist Designation
The seed data lists "Kappa-opioid receptor agonist" as a pharmacological class. Morphine does have measurable KOR activity, but Ki at KOR is approximately 100–600× higher than at MOR (much lower potency). At therapeutic doses, morphine is functionally a selective MOR agonist. The "KOR agonist" classification may mislead; it should ideally be qualified as "weak kappa activity" or removed from primary class. Published Ki values for morphine at human KOR and DOR were not directly retrieved from a single primary paper (class-level inference used). **Specific morphine Ki values at KOR and DOR from a single radioligand binding study should be confirmed before finalizing the pharmacological class.**

### 5. 🟡 MISSING CHEMICAL DATA: SMILES String
SMILES was not returned by the PubChem API tool in this session. Should be populated directly from PubChem CID 5288826. The canonical SMILES can be retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/5288826

### 6. 🟡 SEED DATA: PubChem CID, Formula, Weight, InChIKey All Empty
All four fields were blank in the seed data. All are now confirmed:
- CID: 5288826
- Formula: C₁₇H₁₉NO₃
- MW: 285.34
- InChIKey: BQJCRHHNABKAKU-KBQPJGBKSA-N

### 7. 🟡 SEED DATA: Morphine as Primary ROA Listed as "Intravenous"
Clinical prescribing practice in most settings uses oral morphine (immediate-release or extended-release) as the primary route. IV is standard in hospital/acute care settings but oral is the dominant prescribed route globally. This may reflect a harm-reduction perspective (focusing on misuse routes) or an error. Flagging for editorial review.

### 8. 🟡 CONTROLLED STUDY DATA ON SUBJECTIVE EFFECTS
Published controlled human studies on morphine's subjective effects are limited in number. The Jasinski & Preston (1986) study used IM doses in male non-dependent substance abusers. Generalizability to other populations (opioid-naïve patients, female subjects) is limited. Effect taxonomy items (internal hallucinations, dreaming enhancement, double vision) are consistent with the literature but derive from class-level evidence and user reports rather than controlled morphine-specific studies.

### 9. 🟡 HISTORY: Gates-Tschudi Total Synthesis (1952)
The first total synthesis of morphine by Marshall Gates and Gilg Tschudi (1952, JACS) could not be confirmed via PubMed (pre-database paper). This is well-established historical fact but marked as unverifiable by API.

### 10. 🟡 DYSPNEA INDICATION
Morphine is increasingly studied as a treatment for chronic breathlessness in non-cancer conditions (MABEL trial [Ref 38]). This is an emerging and important indication that may warrant a dedicated clinical uses section in the article.